Metabolite changes associated with resectable pancreatic ductal adenocarcinoma
Metabolite changes associated with resectable pancreatic ductal adenocarcinoma
Introduction: pancreatic ductal adenocarcinoma (PDAC) is insidious, with only 15–20% of those diagnosed suitable for surgical resection as it is either too advanced and has invaded local structures or has already spread to distant sites. The associated tumor microenvironment provides a protective shield which limits the efficacy of chemotherapeutic agents, but also impairs the delivery of nutrients required for the PDAC cells. To compensate for this, metabolic adaptions occur to provide alternative sources of fuel. The aim of this study is to explore metabolomic differences between participants with resectable PDAC compared to healthy volunteers (HV). The objectives were to use nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) to determine if resectable PDAC induces sufficient metabolic adaptations and variations which could be used to discriminate between the two groups.
Methods: plasma samples were collected from fasted individuals with resectable PDAC (n = 23, median age 68 [IQR 56–75], 69.6% male) and HV (n = 24, median age 63 [IQR 58–71], 54.2% male). Samples were analyzed using NMR and the Biocrates MxP Quant 500 kit at University Hospital Southampton.
Results: NMR spectroscopy identified six independent metabolites that significantly discriminated between the PDAC and HV groups, including elevated plasma concentrations of 3-hydroxybutyrate and citrate, with decreased amounts of glutamine and histidine. MS analysis identified 84 metabolites with a significant difference between the PDAC and HV cohorts. The metabolites with a fold change (FC) > 1.5 in the PDAC population were conjugated bile acids (taurocholic acid, glycocholic acid, and glycochenodexoycholic acid).
Discussion: in conclusion, using metabolomics, biochemical differences between resectable PDAC and HV were detected. These differences indicate metabolic plasticity and utilization of alternative fuel sources.
PDAC, adenocarcinoma, metabolite, metabolomics, pancreatic
McDonnell, Declan
b7499481-73e7-4130-897e-cd4200c8a43b
Afolabi, Paul
757e7f01-664c-493e-bc51-c6a2c933dc22
Niazi, Umar
9ec54da2-033e-4172-9748-5be30b7cd53f
Wilding, Sam
a026cae1-cc72-49b5-a52b-ec1d931d72e1
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Swann, Jonathan
7c11a66b-f4b8-4dbf-aa17-ad8b0561b85c
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
Hamady, Zaed Z R
545a1c81-276e-4341-a420-aa10aa5d8ca8
29 March 2025
McDonnell, Declan
b7499481-73e7-4130-897e-cd4200c8a43b
Afolabi, Paul
757e7f01-664c-493e-bc51-c6a2c933dc22
Niazi, Umar
9ec54da2-033e-4172-9748-5be30b7cd53f
Wilding, Sam
a026cae1-cc72-49b5-a52b-ec1d931d72e1
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Swann, Jonathan
7c11a66b-f4b8-4dbf-aa17-ad8b0561b85c
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
Hamady, Zaed Z R
545a1c81-276e-4341-a420-aa10aa5d8ca8
McDonnell, Declan, Afolabi, Paul, Niazi, Umar, Wilding, Sam, Griffiths, Gareth, Swann, Jonathan, Byrne, Chris and Hamady, Zaed Z R
(2025)
Metabolite changes associated with resectable pancreatic ductal adenocarcinoma.
Cancers, 17 (7), [1150].
(doi:10.3390/cancers17071150).
Abstract
Introduction: pancreatic ductal adenocarcinoma (PDAC) is insidious, with only 15–20% of those diagnosed suitable for surgical resection as it is either too advanced and has invaded local structures or has already spread to distant sites. The associated tumor microenvironment provides a protective shield which limits the efficacy of chemotherapeutic agents, but also impairs the delivery of nutrients required for the PDAC cells. To compensate for this, metabolic adaptions occur to provide alternative sources of fuel. The aim of this study is to explore metabolomic differences between participants with resectable PDAC compared to healthy volunteers (HV). The objectives were to use nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) to determine if resectable PDAC induces sufficient metabolic adaptations and variations which could be used to discriminate between the two groups.
Methods: plasma samples were collected from fasted individuals with resectable PDAC (n = 23, median age 68 [IQR 56–75], 69.6% male) and HV (n = 24, median age 63 [IQR 58–71], 54.2% male). Samples were analyzed using NMR and the Biocrates MxP Quant 500 kit at University Hospital Southampton.
Results: NMR spectroscopy identified six independent metabolites that significantly discriminated between the PDAC and HV groups, including elevated plasma concentrations of 3-hydroxybutyrate and citrate, with decreased amounts of glutamine and histidine. MS analysis identified 84 metabolites with a significant difference between the PDAC and HV cohorts. The metabolites with a fold change (FC) > 1.5 in the PDAC population were conjugated bile acids (taurocholic acid, glycocholic acid, and glycochenodexoycholic acid).
Discussion: in conclusion, using metabolomics, biochemical differences between resectable PDAC and HV were detected. These differences indicate metabolic plasticity and utilization of alternative fuel sources.
Text
cancers-17-01150
- Version of Record
More information
Accepted/In Press date: 28 March 2025
Published date: 29 March 2025
Keywords:
PDAC, adenocarcinoma, metabolite, metabolomics, pancreatic
Identifiers
Local EPrints ID: 500654
URI: http://eprints.soton.ac.uk/id/eprint/500654
ISSN: 2072-6694
PURE UUID: 133d1f3b-12c1-42ba-bf12-ed665d467422
Catalogue record
Date deposited: 08 May 2025 16:38
Last modified: 30 Aug 2025 02:17
Export record
Altmetrics
Contributors
Author:
Declan McDonnell
Author:
Paul Afolabi
Author:
Umar Niazi
Author:
Zaed Z R Hamady
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics